Skip to main content
ENDO 2026 Main banner

Bone and Mineral Metabolism

SUN-769 - Global Prevalence Estimates for Post-Surgical and Non-Surgical Chronic Hypoparathyroidism (Hypopt): A Systematic Literature Review and Meta-Analysis

Sunday, June 14, 2026
9:00 AM - 4:00 PM CT
Location: ENDOExpo; Poster Floor
Disclosure(s):
Subhara Raveendran, PhD: Ascendis Pharma: Employee (any industry) ()


Objectives: Chronic hypoparathyroidism (hypoPT) is an endocrine disease caused by insufficient levels of parathyroid hormone. Chronic hypoPT has multiple etiologies, including removal of or damage to parathyroid glands during surgery (“post-surgical”; most common); and genetic, autoimmune, or idiopathic causes (“non-surgical”). Epidemiological data remains limited given these complexities, and existing evidence suggests prevalence may be increasing over time. This study aimed to conduct a meta-analysis of existing literature to estimate the global chronic hypoPT prevalence by subtype.

Methods: A systematic literature search was conducted in PubMed and Embase to identify relevant literature reporting global non-surgical and/or post-surgical chronic hypoPT prevalence in pediatric and adult populations. Following PRISMA guidelines, articles were reviewed against inclusion criteria. Prevalence estimates were analyzed separately by non-surgical and post-surgical subtypes. Prior to the meta-analysis, the number of chronic hypoPT cases reported in studies were time-trend adjusted to 2025 based on annual growth rates derived from historical data. Global and regional pooled prevalence rates by subtype with 95% confidence intervals (CI) were estimated via random effect meta-analyses. Study heterogeneity was evaluated visually using forest plots, and quantitatively via Cochran’s Q and I2 statistics.

Results: A total of 15 studies met the inclusion criteria (11 for post-surgical and 11 for non-surgical subtypes). The meta-analysis estimated pooled global prevalence rates of 22.2 per 100k (95% CI: 18.6-25.9) for post-surgical chronic hypoPT and 6.4 per 100k (95% CI: 4.2-8.6) for non-surgical chronic hypoPT, with high heterogeneity within both subtypes. For post-surgical chronic hypoPT, regional analyses estimated the highest prevalence in Northern America (25.9 per 100k (95% CI: 12.7-39.2)) and lowest in Europe (20.8 per 100k (95% CI: 15.3-26.2)). Regional variations were also observed for non-surgical chronic hypoPT, with the highest prevalence in Northern America (10.0 per 100k (95% CI: 9.8-10.1)) and lowest in Asia (3.2 per 100k (95% CI: 1.3-5.0)).

Conclusion: Pooled global post-surgical chronic hypoPT prevalence (22.2 per 100k) was higher than the prevalence of non-surgical chronic hypoPT (6.4 per 100k). High heterogeneity likely reflected variable case definitions across studies, particularly ICD-based diagnoses versus treatment-inferred diagnoses. Moreover, differences in post-surgical chronic hypoPT rates specifically may reflect varying thyroidectomy rates and surgical expertise. Although available data remain limited, this analysis offers critical updated global prevalence estimates for chronic hypoPT, addressing a key evidence gap and supporting improved understanding of its true disease burden.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*